CARISMA Therapeutics (STU:W2J) EV-to-Revenue : -0.08 (As of Jun. 06, 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CARISMA Therapeutics's enterprise value is €-1.15 Mil. CARISMA Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €13.93 Mil. Therefore, CARISMA Therapeutics's EV-to-Revenue for today is -0.08.

The historical rank and industry rank for CARISMA Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:W2J' s EV-to-Revenue Range Over the Past 10 Years
Min: -7.94 Med: 1.24 Max: 20.61
Current: -0.09

During the past 4 years, the highest EV-to-Revenue of CARISMA Therapeutics was 20.61. The lowest was -7.94. And the median was 1.24.

STU:W2J's EV-to-Revenue is ranked better than
92.38% of 1037 companies
in the Biotechnology industry
Industry Median: 7.83 vs STU:W2J: -0.09

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), CARISMA Therapeutics's stock price is €1.057. CARISMA Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.34. Therefore, CARISMA Therapeutics's PS Ratio for today is 3.07.

CARISMA Therapeutics EV-to-Revenue Historical Data

The historical data trend for CARISMA Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics EV-to-Revenue Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

2.98

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial							-0.71	18.40	5.51	2.98	3.00

Competitive Comparison of CARISMA Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, CARISMA Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's EV-to-Revenue falls into.

CARISMA Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CARISMA Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-1.148	/	13.93
	=	-0.08

CARISMA Therapeutics's current Enterprise Value is €-1.15 Mil.
CARISMA Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.93 Mil.

CARISMA Therapeutics (STU:W2J) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CARISMA Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.057	/	0.344
	=	3.07

CARISMA Therapeutics's share price for today is €1.057.
CARISMA Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.34.

CARISMA Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (STU:W2J) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (STU:W2J) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CARM:USA W2J:Germany

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics (STU:W2J) Headlines

No Headlines